2025
Association between prostate radiation therapy and survival among patients with metastatic prostate cancer by extent of disease burden.
Palencia P, Zhao X, Kandala K, Smani S, Sivanesan N, Cavallo J, Leapman M. Association between prostate radiation therapy and survival among patients with metastatic prostate cancer by extent of disease burden. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e17123.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyProstate radiation therapyMetastatic prostate cancerOverall survivalRadiation therapyProstate cancerM1c diseaseTreatment modalitiesRT to ADTTreated with androgen deprivation therapyAssociated with improved overall survivalHormone-sensitive prostate cancerAssociated with poor overall survivalPrimary local therapyExternal beam radiotherapyGleason grade groupCompare overall survivalNational Cancer DatabaseProstate cancer metastasisLog-rank testDisease burdenKaplan-Meier curvesCox proportional hazards modelsLow disease burdenARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC).
Armstrong A, Petrylak D, Shore N, Szmulewitz R, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Croitoru R, Wu R, Kalac M, Tang Y, Stenzl A, Azad A. ARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC). Journal Of Clinical Oncology 2025, 43: 5005-5005. DOI: 10.1200/jco.2025.43.16_suppl.5005.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyOverall survivalOS analysisRadiographic progression-free survivalHormone-sensitive prostate cancerLong-term follow-upGlobal phase 3Low-volume patientsOpen-label enzalutamideProgression-free survivalEfficacy of enzalutamideMedian Follow-UpOpen-label extensionKaplan-Meier methodLong-term efficacyStandard-of-careClinically relevant subgroupsCox regression modelsFollow-up dataARCH trialDocetaxel useMedian OSAndrogen deprivationDisease volumeProstate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
Carlsson S, Barata P, Bryce A, George D, Gillessen S, Loeb S, Montgomery B, Morris D, Riaz I, Palapattu G, Schoen M, Washington Iii S, Cornell B, Levine R, Aggarwal P, McGowan T, Cotter M, Thompson B, Devgan G, Russell D, Kuperman G, Lenero E, Iwata K, Miyahira A, Soule H, Carithers G, Oh W, Agarwal N. Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer. JCO Oncology Practice 2025, op2500050. PMID: 40315399, DOI: 10.1200/op-25-00050.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerProstate Cancer FoundationHormone-sensitive prostate cancerCombination therapyProstate cancerPatients treated with combination therapyAndrogen receptor pathway inhibitorsBenefit of combination therapyQuality of lifeSignificant survival improvementUrban-dwelling patientsPreserving quality of lifeEnhanced survival outcomesGuideline-concordant careMeta-analysesRandomized Controlled TrialsDeprivation therapyEvidence-based therapiesSurvival outcomesTreatment utilization patternsSurvival improvementClinical trialsGlobal RegistryPathway inhibitorCombined treatmentEnzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer
Azad A, Petrylak D, Iguchi T, Shore N, Villers A, Gomez-Veiga F, Alcaraz A, Alekseev B, Szmulewitz R, Holzbeierlein J, Rosbrook B, Ma J, Zohren F, El-Chaar N, Haas G, Stenzl A, Armstrong A. Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer. JAMA Network Open 2025, 8: e258751. PMID: 40332939, PMCID: PMC12059972, DOI: 10.1001/jamanetworkopen.2025.8751.Peer-Reviewed Original ResearchConceptsMetastatic hormone-sensitive prostate cancerProstate-specific antigen levelRadiographic progression-free survivalUndetectable prostate-specific antigenAndrogen deprivation therapyProstate-specific antigenProstate-specific antigen declineClinical outcomesOverall survivalProstate cancerClinical trialsHazard ratioPatients treated with enzalutamideHormone-sensitive prostate cancerPhase 3 randomized clinical trialAssociated with improved survivalStudy enrollmentProgression-free survivalMetastatic prostate cancerRadiographic disease progressionClinical end pointsPost hoc secondary analysisRandomized clinical trialsReduced riskSecondary analysisAdvances in Current Treatment Paradigms for Metastatic Hormone-Sensitive Prostate Cancer
Smani S, DuBois J, Ajjawi I, Sohoni N, Choksi A, Lokeshwar S, Kim I, Renzulli J. Advances in Current Treatment Paradigms for Metastatic Hormone-Sensitive Prostate Cancer. Journal Of Clinical Medicine 2025, 14: 2565. PMID: 40283395, PMCID: PMC12028174, DOI: 10.3390/jcm14082565.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyAndrogen receptor signaling inhibitorsHormone-sensitive prostate cancerCombination therapyProstate cancerHigh-volume metastatic diseaseProgression to castration resistancePSMA PET-CTLow-volume diseaseOverall survival benefitCurrent treatment paradigmDetection of metastasesBalance treatment efficacyPersonalized treatment strategiesOptimal treatment selectionStandard of careCytoreductive prostatectomyDoublet therapyPrecision-based approachesTriplet therapyCastration resistanceDeprivation therapyMetastatic diseaseRadiation therapyTime to metastasis after prostatectomy (TTM) and survival outcomes in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of the SWOG 1216 phase 3 trial.
Sayegh N, Jo Y, Swami U, Hage Chehade C, Ozay Z, Gebrael G, Maughan B, Plets M, Hussain M, Dorff T, Lara P, Goldkorn A, Lerner S, Agarwal N. Time to metastasis after prostatectomy (TTM) and survival outcomes in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of the SWOG 1216 phase 3 trial. Journal Of Clinical Oncology 2025, 43: 173-173. DOI: 10.1200/jco.2025.43.5_suppl.173.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression-free survivalOverall survivalMetachronous diseaseMetastatic hormone-sensitive prostate cancerInitial prostate cancer diagnosisTiming of metastatic diseaseHormone-sensitive prostate cancerSubgroups of ptsTime of prostatectomyTime to metastasisCox proportional hazards modelsProstate cancer diagnosisProportional hazards modelDeprivation therapyGleason scoreMetastatic diseaseMetastatic recurrenceMetastatic diagnosisPrognostic factorsPerformance statusProstate cancerPrognostic valueSurvival outcomesProstatectomyEvaluating survival post-7 mo PSA response, stratified by response, disease extent, and intermittent vs. continuous ADT in mHSPC: The S9346 trial.
Sokolova A, Tangen C, Hussain M, Sweeney C, Dorff T, Thompson I, Lerner S. Evaluating survival post-7 mo PSA response, stratified by response, disease extent, and intermittent vs. continuous ADT in mHSPC: The S9346 trial. Journal Of Clinical Oncology 2025, 43: 268-268. DOI: 10.1200/jco.2025.43.5_suppl.268.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerPSA responseAndrogen deprivation therapyProstate-specific antigenContinuous androgen deprivation therapyContinuous ADTOverall survivalDisease extentCox regressionHormone-sensitive prostate cancerAssociated with worse OSDe-intensification strategiesBaseline clinical featuresSubsets of patientsTreatment effectsDeprivation therapyImproved OSExtensive diseaseMinimal diseasePrognostic significanceProstate cancerOptimal therapyCox analysisLymph nodesPrognostic marker
2024
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216
Swami U, Jo Y, Narang A, Plets M, Hage Chehade C, Gebrael G, Gupta S, Myint Z, Tangen C, Lara P, Thompson I, Hussain M, Dorff T, Lerner S, Agarwal N. Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216. European Urology Oncology 2024, 8: 612-615. PMID: 39521639, PMCID: PMC12059143, DOI: 10.1016/j.euo.2024.10.013.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerHormone-sensitive prostate cancerAndrogen deprivation therapyBody mass indexAssociated with better OSHigher Body Mass IndexOverall survivalPhase 3 trialProstate cancerMass indexMetastatic castration-resistant prostate cancerAssociated with better overall survivalBaseline prostate-specific antigenCastration-resistant prostate cancerNormal body mass indexIncidence of visceral metastasesBaseline body mass indexZubrod performance statusCorrelation of body mass indexAnalysis of patient-level dataProstate-specific antigenGroup of patientsPost hoc exploratory analysisRisk of deathMedian OSCirculating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski J, Ingles S, Triche T, MacVicar G, Vaena D, Crispino A, McConkey D, Lara P, Hussain M, Quinn D, Dorff T, Lerner S, Thompson I, Agarwal N. Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Network Open 2024, 7: e2437871. PMID: 39374015, PMCID: PMC11581504, DOI: 10.1001/jamanetworkopen.2024.37871.Peer-Reviewed Original ResearchConceptsMetastatic hormone-sensitive prostate cancerMetastatic castration-resistant prostate cancerCirculating tumor cell countCirculating Tumor CellsHormone-sensitive prostate cancerTumor cell countOverall survivalProstate cancerPrognostic valueCTC countsPrognostic factorsProgression to metastatic castration-resistant prostate cancerDiagnosed mHSPCPeripheral blood circulating tumor cellsClinical trialsBlood circulating tumor cellsCastration-resistant prostate cancerPrognostic studyCell countBaseline CTC countProgression-free survivalLines of therapyEnhanced overall survivalProstate-specific antigenIncreased prognostic valueBone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer
Gebrael G, Jo Y, Swami U, Plets M, Chehade C, Narang A, Gupta S, Myint Z, Sayegh N, Tangen C, Hussain M, Dorff T, Lara P, Lerner S, Thompson I, Agarwal N. Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer. JAMA Network Open 2024, 7: e2419966. PMID: 38980676, PMCID: PMC11234233, DOI: 10.1001/jamanetworkopen.2024.19966.Peer-Reviewed Original ResearchConceptsProgression-free survivalAndrogen deprivation therapyProstate-specific antigenHormone-sensitive prostate cancerBone painOverall survivalPost hoc secondary analysisProstate cancerSurvival outcomesPain statusAssociated with shorter progression-free survivalClinical trialsPresence of bone painProstate-specific antigen levelAssociated with worse overall survivalCastration-resistant prostate cancerShorter progression-free survivalIntention-to-treat populationSecondary analysisZubrod performance statusHigh-volume diseaseCompare survival outcomesCox proportional hazards regression modelsSecondary end pointsProportional hazards regression modelsCorrelation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study.
Swami U, Jo Y, Narang A, Plets M, Hage Chehade C, Gebrael G, Gupta S, Myint Z, Tangen C, Lara P, Thompson I, Hussain M, Dorff T, Lerner S, Agarwal N. Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study. Journal Of Clinical Oncology 2024, 42: 5081-5081. DOI: 10.1200/jco.2024.42.16_suppl.5081.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerBody mass indexBody mass index cohortZubrod performance statusCorrelation of body mass indexPhase III studyOverall survivalSurvival outcomesGleason scoreIII studiesPerformance statusProstate cancerMetastatic hormone-sensitive prostate cancer settingAssociated with improved survival outcomesMetastatic castration-resistant prostate cancerMultivariate analysisHormone-sensitive prostate cancerAssociated with better OSRandomized phase III studyCastration-resistant prostate cancerNormal body mass indexCategorized body mass indexPrognostication of patientsAssociation of obesityDisease burdenThree- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide
Parikh M, Tangen C, Hussain M, Gupta S, Callis S, Jo Y, Harzstark A, Paller C, George S, Zibelman M, Cheng H, Maughan B, Zhang J, Pachynski R, Bryce A, Lin D, Quinn D, Lerner S, Thompson I, Dorff T, Lara P, Agarwal N. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. European Urology Oncology 2024, 7: 1097-1104. PMID: 38523017, PMCID: PMC12037053, DOI: 10.1016/j.euo.2024.03.001.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerHormone-sensitive prostate cancerProstate-specific antigenAndrogen deprivation therapyProstate-specific antigen levelOverall survivalProstate cancerDeprivation therapyComplete responseAntigen levelsNo responseTreatment of metastatic hormone-sensitive prostate cancerLow prostate-specific antigen levelsResponse to androgen deprivation therapyAssociated with improved OSPSA responsePhase 3 randomized trialPhase 3 clinical trialsEarly identification of patientsAssociated with OSHigher risk of deathIdentification of patientsResponse to treatmentRisk of deathOS associationBaseline bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer (mHSPC): Patient-level analysis of SWOG 1216 trial.
Gebrael G, Jo Y, Swami U, Plets M, Hage Chehade C, Narang A, Gupta S, Myint Z, Sayegh N, Tangen C, Hussain M, Dorff T, Lara P, Lerner S, Thompson I, Agarwal N. Baseline bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer (mHSPC): Patient-level analysis of SWOG 1216 trial. Journal Of Clinical Oncology 2024, 42: 188-188. DOI: 10.1200/jco.2024.42.4_suppl.188.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerProgression-free survivalAndrogen deprivation therapyBone painOverall survivalGleason scoreProstate cancerPrognostic markerAssociated with decreased PFSDisease burdenMedian progression-free survivalHormone-sensitive prostate cancerCastration-resistant prostate cancerCox proportional hazards modelsConfidence intervalsPatient-level analysisProportional hazards modelDeprivation therapyHigher disease burdenBone metastasesPain statusSurvival outcomesPatient-level dataTreatment intensificationPrognostic variables
2023
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES
Armstrong A, Iguchi T, Azad A, Villers A, Alekseev B, Petrylak D, Szmulewitz R, Alcaraz A, Shore N, Holzbeierlein J, Gomez-Veiga F, Rosbrook B, Zohren F, Haas G, Gourgiotti G, El-Chaar N, Stenzl A. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES. European Urology 2023, 84: 229-241. PMID: 37179240, DOI: 10.1016/j.eururo.2023.04.002.Peer-Reviewed Original ResearchConceptsHormone-sensitive prostate cancerAndrogen deprivation therapyRadiographic progression-free survivalMetastatic hormone-sensitive prostate cancerOligometastatic hormone-sensitive prostate cancerOverall survivalProstate cancerDeprivation therapyHazard ratioAndrogen receptor inhibitionEarly treatment intensificationEfficacy of enzalutamideRisk of undertreatmentSystemic treatment strategiesSecondary efficacy endpointsPhase 3 studyProgression-free survivalNumber of metastasesConfidence intervalsProportional hazards modelPost Hoc AnalysisEfficacy endpointOligometastatic diseaseSecondary endpointsTreatment intensificationPersonalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics
Lokeshwar S, Choksi A, Haltstuch D, Rahman S, Press B, Syed J, Hurwitz M, Kim I, Leapman M. Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics. World Journal Of Urology 2023, 41: 2007-2019. PMID: 37160450, DOI: 10.1007/s00345-023-04409-9.Peer-Reviewed Original ResearchConceptsMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyHormone-sensitive prostate cancerSensitive prostate cancerPositron emission tomographyConventional computerized tomographyDocetaxel chemotherapyClinical trialsProstate cancerCombination of ADTBackbone of treatmentCytoreductive radical prostatectomySequencing of therapyFirst-line treatmentEvaluation of patientsClinical practice guidelinesOngoing clinical trialsAndrogen receptor antagonistPubMed Medline databaseDeprivation therapyInitial managementOverall survivalStaging evaluationBone scanRandomized trialsManagement of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
Gillessen S, Bossi A, Davis I, de Bono J, Fizazi K, James N, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis E, Aparicio A, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow R, Bulbul M, Caffo O, Castellano D, Castro E, Cheng H, Chi K, Chowdhury S, Clarke C, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke O, Evans C, Fanti S, Feng F, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman M, Horvath L, Hussain M, Jereczek-Fossa B, Jones R, Kanesvaran R, Kellokumpu-Lehtinen P, Khauli R, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans A, Morris M, Mrabti H, Mukherji D, Murphy D, Murthy V, Nguyen P, Oh W, Ost P, O'Sullivan J, Padhani A, Pezaro C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Sharifi N, Skoneczna I, Soule H, Spratt D, Srinivas S, Sternberg C, Steuber T, Suzuki H, Sydes M, Taplin M, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale C, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu E, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European Journal Of Cancer 2023, 185: 178-215. PMID: 37003085, DOI: 10.1016/j.ejca.2023.02.018.Peer-Reviewed Original ResearchConceptsAdvanced Prostate Cancer Consensus ConferenceMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerProstate Cancer Consensus ConferenceAdvanced prostate cancerHormone-sensitive prostate cancerOligometastatic prostate cancerProstate cancerNon-metastaticConsensus conferenceConsensus questionsTreatment optionsMetastatic hormone-sensitive prostate cancerAdvanced prostate cancer managementInternational prostate cancer expertsLocally advanced prostate cancerAdvanced prostate cancer treatmentEffects of hormone therapySide effects of hormone therapyMetastatic hormone-sensitiveOligoprogressive prostate cancerProstate cancer expertsProstate cancer managementLevel 1 evidenceNovel treatment options
2022
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
Gillessen S, Bossi A, Davis I, de Bono J, Fizazi K, James N, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis E, Aparicio A, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow R, Bulbul M, Caffo O, Castellano D, Castro E, Cheng H, N. K, Chowdhury S, Clarke C, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke O, Evans C, Fanti S, Feng F, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman M, Horvath L, Hussain M, Jereczek-Fossa B, Jones R, Kanesvaran R, Kellokumpu-Lehtinen P, Khauli R, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans A, Morris M, Mrabti H, Mukherji D, Murphy D, Murthy V, Nguyen P, Oh W, Ost P, O’Sullivan J, Padhani A, Pezaro C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Sharifi N, Skoneczna I, Soule H, Spratt D, Srinivas S, Sternberg C, Steuber T, Suzuki H, Sydes M, Taplin M, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale C, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu E, Zapatero A, Zilli T, Omlin A. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. European Urology 2022, 83: 267-293. PMID: 36494221, PMCID: PMC7614721, DOI: 10.1016/j.eururo.2022.11.002.Peer-Reviewed Original ResearchConceptsAdvanced Prostate Cancer Consensus ConferenceAdvanced prostate cancerProstate Cancer Consensus ConferenceLocally advanced prostate cancerCastration-resistant prostate cancerProstate cancerBiochemical relapseSide effectsHormone therapyTreatment optionsMetastatic hormone-sensitive prostate cancerNonmetastatic castration-resistant prostate cancerMetastatic castration-resistant prostate cancerClinical managementInternational prostate cancer expertsLack high-level evidenceHormone-sensitive prostate cancerProstate cancer treatment decision-makingTreatment decisionsHigh riskConsensus conferenceOligoprogressive prostate cancerProstate cancer expertsLocally advanced diseaseManagement of patients1398P Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES
Petrylak D, Azad A, Szmulewitz R, Iguchi T, Shore N, Holzbeierlein J, Alekseev B, El-Chaar N, Rosbrook B, Ma J, Zohren F, Haas G, Stenzl A, Armstrong A. 1398P Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES. Annals Of Oncology 2022, 33: s1183-s1184. DOI: 10.1016/j.annonc.2022.07.1884.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyOverall survivalLow prostate-specific antigen levelsHormone-sensitive prostate cancerPrior androgen deprivation therapyProstate-specific antigen levelDeprivation therapyAntigen levelsProstate cancerEnzalutamidePatientsTherapyCancerManagement of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience
Guin S, Liaw B, Jun T, Ayers K, Patel B, O’Connell T, Deitz M, Klein M, Mullaney T, Prentice T, Newman S, Fink M, Zhou X, Schadt E, Chen R, Oh W. Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience. PLOS ONE 2022, 17: e0264800. PMID: 35984843, PMCID: PMC9390935, DOI: 10.1371/journal.pone.0264800.Peer-Reviewed Original ResearchConceptsMetastatic hormone-sensitive prostate cancerNovel hormonal agentsPSA progression-free survivalDe novo metastatic hormone-sensitive prostate cancerHormone-sensitive prostate cancerUpfront docetaxelOverall survivalPrognostic valueProstate cancerPSA PFSMultivariable Cox proportional hazards modelsPost-treatment PSA levelMount Sinai Health SystemCox proportional hazards modelDocetaxel-treated patientsPost-treatment PSASensitive prostate cancerProgression-free survivalSinai Health SystemSingle-center experienceKaplan-Meier methodStandard of careProportional hazards modelReal-world managementDocetaxel regimensManagement of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021
Gillessen S, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow R, Bulbul M, Caffo O, Chi K, Clarke C, Clarke N, Davis I, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke O, Evans C, Fanti S, Feng F, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman M, Hussain M, James N, Jones R, Kanesvaran R, Khauli R, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans A, Morris M, Mottet N, Mrabti H, Murphy D, Murthy V, Oh W, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg C, Suzuki H, Sweeney C, Sydes M, Taplin M, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology 2022, 82: 115-141. PMID: 35450732, DOI: 10.1016/j.eururo.2022.04.002.Peer-Reviewed Original ResearchConceptsAdvanced Prostate Cancer Consensus ConferenceProstate Cancer Consensus ConferenceAdvanced prostate cancerMetastatic hormone-sensitive prostate cancerProstate cancerConsensus conferenceTreatment optionsDiagnosed metastatic hormone-sensitive prostate cancerManagement of advanced prostate cancerTreatment of advanced prostate cancerProstate-specific membrane antigen ligandHormone-sensitive prostate cancerInternational prostate cancer expertsConsensus questionsProstate cancer expertsLevel 1 evidenceManagement of patientsLocation of diseaseExpert panel votesClinically relevant areasSupplementation guidelinesClinical evidencePatient characteristicsAntigenic ligandsClinical trials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply